JJ, H., RK, K., B, T., M, C., GK, D., J, S., . . . GK, A. (2020). Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. The oncologist, 25(12), e1825. https://doi.org/10.1634/theoncologist.2020-0521
Chicago Style (17th ed.) CitationJJ, Harding, et al. "Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma." The Oncologist 25, no. 12 (2020): e1825. https://doi.org/10.1634/theoncologist.2020-0521.
MLA (9th ed.) CitationJJ, Harding, et al. "Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma." The Oncologist, vol. 25, no. 12, 2020, p. e1825, https://doi.org/10.1634/theoncologist.2020-0521.
Warning: These citations may not always be 100% accurate.
